SASKATOON, Saskatchewan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce that it has entered into a non-binding letter of intent (“LOI”) to acquire from an arm’s length vendor (the “Vendor”) the prescription files, patient records, and related operational data (the “Pharmacy Files”) of a pharmacy located in the same community as one of PharmaCorp’s existing PharmaChoice-bannered pharmacies in Western Canada (the “Proposed Acquisiti ...

Core Viewpoint - CVS Health Corporation is experiencing a positive outlook from various analysts, with multiple price target upgrades suggesting significant growth potential in the healthcare sector [2][3][4]. Analyst Ratings and Price Targets - Kevin Caliendo from UBS set a price target of $97 for CVS, indicating a potential increase of approximately 24% from its current price of $78.24 [2][6]. - Wolfe Research raised its price target from $85 to $100, reflecting strong market sentiment towards CVS [2][6]. - Leerink Partners increased their price objective from $86 to $95, maintaining an "outperform" rating [3]. - Evercore ISI also raised their price target from $85 to $95, assigning an "outperform" rating [3]. Market Sentiment and Stock Performance - Despite the positive outlook from several analysts, Zacks Research downgraded CVS from a "strong-buy" to a "hold" rating, indicating some caution in the market [4][6]. - The stock's current price of $78.24 reflects a 2.23% increase, with a trading volume of 12.58 million shares on the NYSE [4]. - CVS's market capitalization is approximately $99.32 billion, highlighting its significant presence in the healthcare industry [5]. Stock Volatility - The stock has fluctuated between a low of $78.22 and a high of $80.50 today, with a 52-week range of $43.56 to $85.15, indicating dynamic market conditions [5].

Core Insights - PharmaCorp RX Inc. reported strong operational momentum and financial performance for Q3 2025, driven by increased revenues, improved margins, and better operating efficiencies [2][4] - The company completed acquisitions of three pharmacies, enhancing its national presence and supporting its coast-to-coast ambitions [2][6][7] - Same-store sales increased by 9.4% year-over-year, and total prescription volumes rose by 7.2% compared to Q3 2024, indicating sustained growth in patient engagement [9] Financial Highlights - The reported net loss for the quarter reflects investments in corporate infrastructure and one-time legal fees related to obtaining a credit facility [5][9] - The company raised approximately C$23.0 million through a bought deal public offering, selling 54,855,000 units at C$0.42 per unit [8] - Solid pharmacy-level contribution margins and a disciplined approach to EBITDA multiples across acquisitions support PharmaCorp's long-term growth model [9] Operational Update - Key investments were made in systems, personnel, and integration processes to facilitate scalable national growth [5] - The company operates seven PharmaChoice Canada bannered pharmacies and aims to acquire more pharmacies, rebranding them under the PharmaChoice Canada platform [12]

Executive Transition - PharmaCorp RX Inc. announced the appointment of Paul Dale as President and Chief Operating Officer effective December 1, 2025, as Calvin LeRoux transitions to a one-year role as Strategic Advisor to the CEO [1][2] - Paul Dale has been with PharmaCorp since its inception as Chief Operating Officer and will now take on broader leadership responsibilities to support the company's national expansion strategy [2] - Calvin LeRoux will assist in the transition and continue to provide guidance on strategic initiatives and matters related to PharmaChoice Canada in his new advisory role [2] New Appointment - Sophia Sigler will join PharmaCorp as Director of Business Development effective December 1, 2025, leading business development initiatives, including sourcing acquisition opportunities and managing the transaction pipeline [2] Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [3] - The company operates seven PharmaChoice Canada bannered pharmacies and aims to acquire both bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform [3]

Group 1: Thanksgiving Closures - Most federal and financial institutions will pause operations on Thanksgiving Day, including banks, post offices, and the stock market (NYSE and Nasdaq) [2] - Major shipping carriers such as United Parcel Service Inc. and FedEx Corp. will suspend standard pickup and delivery services on this day [2] - Retail giants like Walmart Inc., Target Corp., Costco Wholesale Corp., Macy's Inc., and Kohl's Corp. will remain closed on Thanksgiving Day [3] Group 2: Thanksgiving Openings - Many grocery chains, including Kroger Co., Whole Foods, and Sprouts Farmers Market Inc., will be open on Thanksgiving, albeit with reduced hours [4] - Select pharmacies like CVS Health Corp. and Walgreens will operate, but customers should check local store hours as pharmacy counters may be closed [4] Group 3: Black Friday Operations - Business operations will resume on Black Friday, November 28, with banks and post offices reopening for regular service [6] - The stock market will open but will close early at 1 p.m. ET on Black Friday [6] - Major retailers, including Walmart and Target, will open at 6 a.m. for Black Friday deals, marking the start of the shopping season [6]

Core Points - Thanksgiving is a federal holiday in the United States, celebrated on the fourth Thursday of November, with November 27 being the date in 2025 [3] - Various services, including mail delivery and banking, will be closed on Thanksgiving, with exceptions for certain express services [4][6][7][8] Service Availability - The United States Postal Service (USPS) will not deliver mail on Thanksgiving, except for Priority Mail Express [4] - UPS and FedEx will also be closed, with only UPS Express Critical and FedEx Custom Critical services available [6] - Banks will be closed, but ATMs and online banking will remain accessible [7] Retail and Grocery Store Operations - Many grocery stores and retailers will be open on Thanksgiving, with varying hours [12] - Notable stores that will be open include Whole Foods, Sprouts, Kroger, Meijer, and Walmart, among others [12] - Some pharmacies, like Walgreens, will have 24-hour locations open, while CVS will operate with limited hours [11][12]

Guardian Pharmacy Services (NYSE:GRDN) FY Conference Summary Company Overview - Guardian Pharmacy Services is a leading long-term care pharmacy provider with over 50 pharmacy operations nationally, primarily focused on assisted living and memory care markets [3][4] - The company holds approximately 13% market share in the assisted living end market and aims to expand to 20-30% over time [3][4] Core Business Model - The business model is centered around providing specialized pharmacy services tailored to the needs of frail and elderly residents in assisted living facilities [6][10] - Guardian's operations leverage scale through purchasing, reimbursement, analytics tools, and strong sales relationships with national accounts [6][10] Market Focus - The assisted living market was chosen due to its significant growth over the past 20 years, with a total addressable market (TAM) of approximately one million residents [10] - The average resident is now older (85+) and takes an average of 14 prescriptions, indicating a shift in the acuity level of residents [10][32] Competitive Landscape - Guardian competes with independent operators who lack the scale and resources to provide the same level of service and analytics [12][58] - The company believes there is ample room for multiple competitors in the assisted living market, despite the presence of larger peers [56][58] Growth Strategy - Organic growth is driven by increasing market share in existing markets and expanding into contiguous markets [15][16] - The company tracks market share using NICMAP data and aims for 50% or more in mature markets [15] - Recent acquisitions in the Pacific Northwest were driven by demand from larger national and regional accounts [22][24] Resident Adoption and Service Efficiency - The current resident adoption rate of Guardian's services is around 89%, with efforts to increase this in new facilities [28] - The company utilizes a tech-enabled platform to ensure safe medication administration, significantly reducing errors [67][70] Financial Outlook - The Inflation Reduction Act (IRA) is expected to impact revenue but not EBITDA, with the company confident in offsetting headwinds through operational efficiencies [38][49] - The company has increased guidance based on favorable organic growth trends and successful flu vaccine clinics [50][52] Adjacent Market Opportunities - Guardian is exploring opportunities in adjacent markets such as PACE and hospice, with ongoing efforts to improve service delivery in these areas [54][55] Conclusion - Guardian Pharmacy Services is well-positioned in the long-term care pharmacy market, with a clear strategy for growth through market share expansion, operational efficiencies, and a focus on specialized services for assisted living facilities [4][10][54]

Summary of Key Points from the Greater China Healthcare Corporate Day Industry Overview - **Industry**: Healthcare in Greater China, including biopharma, CROs, medtech, services, pharmacies, and vaccines - **Sentiment**: Positive sentiment observed in biopharma and CRO sectors, with a focus on undervalued assets following recent market pullbacks [1][1] - **Key Companies**: Wuxi Apptec, Duality, Hansoh, 3SBio, and Tigermed highlighted as companies of interest due to their overseas businesses and partnered assets [1][1] Biopharma Insights - **R&D and Commercialization**: Most biopharma companies are on track with R&D and commercialization efforts. Innovative drug sales and milestone payments are expected to drive near-term revenues [2][2] - **Revenue Projections**: - Huadong Medicine: Rmb2 billion in 2025F and Rmb3 billion in 2026F [2][2] - Sino Biopharm: Projected organic profit growth of over 20% in 2025F and double-digit growth in 2026F [2][2] - **Pricing Pressure**: Volume-based procurement (VBP) continues to impact the generics segment, although biosimilar VBP may remain limited to provincial levels [2][2] CRO and CDMO Performance - **CDMO Orders**: Strong orders and backlog reported for CDMO companies, outperforming CROs due to robust overseas demand [3][3] - **CRO Recovery**: Mild recovery signals noted for domestic CRO demand, despite lagging booking income [3][3] Medtech Sector - **Investor Sentiment**: Generally muted, with some positive indicators in segments like in-vitro diagnosis (IVD) [4][4] - **Company Guidance**: - New Industries: Expected 10% revenue growth in 2026F [4][4] - Yuyue Medical: Anticipates 10% revenue growth for 2025F and higher growth in 2026F [4][4] - **Pharmacies and TCM**: Positive feedback received, with expectations for M&A to drive growth in 2026E [4][4] Company-Specific Updates - **Kelun Biotech**: Maintained sales target of Rmb800 million to Rmb1 billion for sac-TMT (TROP2 ADC) in 2025, with potential for significant milestone payments from 2027F [7][7] - **Abbisko**: R&D progressing well, with potential NDA submission in the US for Pimicotinib expected in Q425 [8][8] - **Hutchmed**: Maintained 2025 oncology revenue guidance of US$270-350 million, with expectations for better performance in 2026 [11][11] - **Zai Lab**: Revised down 2025 revenue guidance to over US$460 million, but noted good growth trends for Zejula [14][14] - **3SBio**: Pfizer planning multiple clinical trials for SSGJ-707, with significant near-term milestone payments expected [24][24] Vaccines and Pharmacies - **CanSino**: Highlighted a diverse product portfolio, including COVID-19 vaccines and other candidates, with healthy inventory levels [39][39] - **Gushengtang**: Targeting 10-15% organic revenue growth in 2026, with notable progress in overseas business [44][44] Risks and Challenges - **Market Risks**: Potential risks include worse-than-expected price cuts from GPO programs, intensified competition, and regulatory challenges [50][50] This summary encapsulates the key insights and projections from the Greater China Healthcare Corporate Day, highlighting the positive sentiment in the biopharma and CRO sectors, along with specific company updates and potential risks in the healthcare industry.

Core Points - PharmaCorp Rx Inc. has received approval from the TSX Venture Exchange for the supplemental listing of 27,427,500 common share purchase warrants, expected to trade under the symbol PCRX.WT starting November 17, 2025 [1][2] - The Offering closed on November 12, 2025, with a total of 54,855,000 Units issued, each consisting of one common share and one-half of a common share purchase warrant, with an exercise price of $0.50 per Warrant Share [2] Company Overview - PharmaCorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [4] - The company operates seven PharmaChoice Canada bannered pharmacies and aims to acquire both bannered and independent pharmacies across Canada, rebranding non-bannered locations under the PharmaChoice Canada platform [4]

Core Points - PharmaCorp Rx Inc. has successfully closed a bought deal public offering, raising approximately C$23.0 million through the sale of 54,855,000 units at C$0.42 per unit, including the full exercise of the over-allotment option [1][2] - Each unit consists of one common share and one-half of a common share purchase warrant, with the warrants allowing the purchase of additional shares at C$0.50 until November 12, 2027 [2] - The net proceeds from the offering will be allocated for future acquisition opportunities and general working capital [3] Offering Details - Directors and officers of the company participated in the offering, acquiring a total of 3,762,010 units, which is classified as a related party transaction [4] - The underwriters received a cash commission of 6.0% of the gross proceeds, totaling C$1,134,633, and were issued 2,026,130 broker warrants [5] - The offering was conducted under a prospectus supplement dated November 7, 2025, linked to the company's base shelf prospectus filed with Canadian securities authorities [6] Company Overview - PharmaCorp is a Canadian pharmacy acquisition platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners [7] - The company operates seven pharmacies under the PharmaChoice Canada banner and aims to expand its network by acquiring both bannered and independent pharmacies [7] - PharmaCorp actively seeks discussions with pharmacy owners considering succession or sale, emphasizing a commitment to seamless transitions [8][9]